Host: HEK293 cells • AA: 72-251 • Tag: N-terminal His • MW: 22.8 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Soluble TNFSF15 (human, recombinant)

Item No. 40855

Product Insert (PDF)
Technical Information
Synonyms
  • TL1
  • TL1A
  • sTL1A
  • TNF Ligand-related Molecule 1
  • Tumor Necrosis Factor Ligand Superfamily Member 15
  • Vascular Endothelial Cell Growth Inhibitor
  • VEGI
  • VEGI192A
Purity
≥95% estimated by SDS-PAGE
Endotoxin Testing
< 1.0 EU/μg, determined by the LAL endotoxin assay
Source
Recombinant human N-terminal His-tagged soluble TNFSF15 expressed in HEK293 cells
Amino Acids
72-251
MW
22.8 kDa
Formulation (Request formulation change)
Lyophilized from sterile PBS, pH 7.4
Host
HEK293 cells
UniProt Accession №
O95150
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    100 µg

    $383

    Add

    1 mg

    $2,489

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Tumor necrosis factor ligand superfamily member 15 (TNFSF15), also known as TNF ligand-related molecule 1 (TL1A), is a type II transmembrane protein and cognate ligand for TNFRSF25, also known as death domain receptor 3 (DR3), with roles in T cell activation and dendritic cell maturation.1,2 It is composed of a cytoplasmic, a transmembrane, and an extracellular domain and forms membrane-bound non-covalent homotrimers. TNFSF15 exists primarily in its membrane-bound form, but can be cleaved by matrix metalloproteinases (MMPs) to release the soluble form (sTL1A).1,3 Both membrane-bound and soluble TNFSF15 bind to TNFRSF25 on the surface of T cells, inducing various signaling pathways resulting in NF-κB activation or apoptosis.3 TNFSF15 also binds to TNF receptor 2 (TNFR2) and TNFR6B, also known as soluble decoy receptor 3 (DcR3), on the surface of T cells to induce pro-inflammatory cytokine production and the inhibition of apoptosis. Intestinal levels of TNFSF15 are increased in patients with inflammatory bowel disease (IBD).4 TNFSF15 SNPs are associated with an increased susceptibility to developing small cell lung cancer (SCLC).5 Cayman’s Soluble TNFSF15 (human, recombinant) protein consists of 199 amino acids and has a calculated molecular weight of 22.8 kDa.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Valatas, V., Kolios, G., and Bamias, G. TL1A (TNFSF15) and DR3 (TNFRSF25): A co-stimulatory system of cytokines with diverse functions in gut mucosal immunity. Front. Immunol. 10:583, (2019).

    2. Lu, H.-J., Chuang, C.-Y., Su, C.-W., et al. Role of TNFSF15 variants in oral cancer development and clinicopathologic characteristics. J. Cell. Mol. Med. 26(21), 5452-5462 (2022).

    3. Xu, W.-D., Li, R., and Huang, A.-F. Role of TL1A in inflammatory autoimmune diseases: A comprehensive review. Front. Immunol. 13:891328, (2022).

    4. Sun, R., Hedl, M., and Abraham, C. TNFSF15 promotes antimicrobial pathways in human macrophages and these are modulated by TNFSF15 disease-risk variants. Cell. Mol. Gastroenterol. Hepatol. 11(1), 249-272 (2021).

    5. Gao, H., Niu, Z., Zhang, Z., et al. TNFSF15 promoter polymorphisms increase the susceptibility to small cell lung cancer: A case-control study. BMC Med. Genet. 20(1), 29 (2019).